People · Operator
Named in public records as an officer, director or promoter · active 2010–2021 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alzheon, Inc. | — | Biotechnology | Series D+ | $172.5M | $1.6B | 2014 |
| Cognition Therapeutics Inc | — | Biotechnology | Series B | $34.9M | $65.4M | 2012 |
| Spinogenix, Inc. | — | Other Health Care | Series A | $24.7M | $31.0M | 2017 |
| Embera Neurotherapeutics, Inc. | — | Pharmaceuticals | Series A | $14.6M | $189.8M | 2011 |
| QR Pharma, Inc. | — | Pharmaceuticals | Seed | $5.1M | $9.6M | 2010 |
| Acumen Pharmaceuticals, Inc. | — | Biotechnology | Pre-Seed | $700K | $38.6M | 2013 |
Franz Hefti at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Franz Hefti on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Franz F. Hefti | 2 | 2 |
| Michael Hoffman | 1 | 11 |
| Paul Blake | 1 | 10 |
| Dennis Langer | 1 | 9 |
| Scott Minick | 1 | 7 |
| Franklin Berger | 1 | 7 |
| Robert Silverman | 1 | 5 |
| Aaron Fletcher | 1 | 5 |
| Christopher Noel Dunn | 1 | 5 |
| Ross Barrett | 1 | 5 |
| Jerre L. Stead | 1 | 4 |
| Joseph Lovett | 1 | 4 |
| Ross P. Barrett | 1 | 4 |
| David Nikodem | 1 | 4 |
| Robert Gailus | 1 | 4 |
| Michael Aceti | 1 | 4 |
| Josh Swartz | 1 | 3 |
| Jean-Pierre Sommadossi | 1 | 3 |
| Steve Young | 1 | 3 |
| Claudine Bruck | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.